Healthcare News

 -- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study...

Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting advancement of Padeliporfin VTP for treatment of locally advanced pancreatic...

- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider...

Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery  SYDNEY, AUSTRALIA, Oct. 23, 2026 ...

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival...

Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off...

Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease progression or death by 71% and risk of death...

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- A 9-year-old boy has become the world's first patient to receive a newly approved implant to treat congenital nystagmus, in a procedure performed at Peking...

PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the...

RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- What began with a single cardiac catheterization laboratory four decades ago has evolved into an advanced cardiovascular program at King...